# US 2022/0064328 A1 · Formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0064328 A1
- Document ID: US20220064328A1
- Status: Published application
- Kind: A1
- Application number: 17/464,789
- Filed: 2021-09-02
- Published: 2022-03-03
- Earliest claimed: 2020-09-02
- Assignees: Anovent Pharmaceutical (U.S.), LLC
- Applicants: Anovent Pharmaceutical (U.S.), LLC
- Inventors: Cai Gu Huang; Hitesh Bhagavanbhai Mangukiya
- Web page: https://patentgrep.com/patent/US20220064328A1

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/52: the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to stable formulations of a solution of nanoantibody drug that is suitable for inhalation and a method of treating acquired thrombotic thrombocytopenic purpura by administering the drug by inhalation using a soft mist inhaler or nebulizer. The pharmaceutical formulation for inhalation comprises caplacizumab.

## Claims

### Claim 1

A liquid, propellant-free pharmaceutical formulation comprising: (A) caplacizumab in an amount ranging from about 0.01 mg/ml to about 100 mg/ml and (B) at least one pharmaceutically acceptable pH-adjusting agent.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the caplacizumab is caplacizumab-yhdp.

### Claim 3 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising a surfactant.

### Claim 4 (depends on 3)

The pharmaceutical formulation of claim 3, wherein the surfactant is selected from the group consisting of polysorbate-80, polysorbate-20, and mixtures thereof.

### Claim 5 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising about 1 mg/ml to about 100 mg/ml sucrose, about 1 mg/ml to about 10 mg/ml of trisodium citrate dihydrate, and about 0.1 mg/ml to about 0.5 mg/ml anhydrous citric acid.

### Claim 6 (depends on 1)

The pharmaceutical formulation of claim 1, comprising from about 50 mg/ml to about 500 mg/ml sucrose, about 5 mg/ml to about 15 mg/ml trisodium citrate dihydrate, and from about 0.1 mg/ml to about 0.5 mg/ml anhydrous citric acid.

### Claim 7 (depends on 1)

The pharmaceutical formulation of claim 1, further comprising about 1 mg/ml to about 20 mg/ml sodium phosphate monobasic monohydrate and about 0.2 mg/ml to about 1.5 mg/ml sodium phosphate dibasic.

### Claim 8 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pH adjusting agent is selected from the group consisting of citric acid, hydrochloric acid, and mixture thereof.

### Claim 9 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pH adjusting agent is citric acid.

### Claim 10 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pH adjusting agent is HCl.

### Claim 11 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the formulation is substantially free of preservatives and stabilizers.

### Claim 12 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the pH is in a range from about 6 to about 7.

### Claim 13 (depends on 12)

The pharmaceutical formulation of claim 12, wherein the pH is in a range from about 6.4 to about 6.6.

### Claim 14 (depends on 1)

A method of treating thrombotic thrombocytopenic purpura comprising administering the pharmaceutical formulation of claim 1 by inhalation.

### Claim 15 (depends on 1)

A method of administering the formulation of claim 1, comprising nebulizing a defined amount of the pharmaceutical formulation with an inhaler by using pressure to force the pharmaceutical formulation through a nozzle to form an inhalable aerosol.

### Claim 16 (depends on 15)

The method of claim 15, wherein the aerosol has a droplet size (d90) of less than about 15 μm.

### Claim 17 (depends on 16)

The method of claim 16, wherein the droplet size (d90) is in a range from about 0.5 μm to about 15 μm.

### Claim 18 (depends on 1)

The pharmaceutical formulation of claim 1 comprising:
an aqueous solution comprising:
caplacizumab-yhdp in an amount ranging from about 100 mg/10 ml to about 200 mg/10 ml,
polysorbate-80 in an amount ranging from about 1 mg/10 ml to about 2 mg/10 ml,
sucrose in an amount ranging from about 620 mg/10 ml to about 1240 mg/10 ml,
trisodium citrate dihydrate in an amount ranging from about 49.1 mg/10 ml to about 98.2 mg/10 ml, and
anhydrous citric acid in an amount ranging from about 1.8 mg/10 ml to about 3.6 mg/ml;
wherein the pH of the pharmaceutical formulation is about 6.5.

### Claim 19 (depends on 1)

The pharmaceutical formulation of claim 1 comprising:
an aqueous solution comprising:
caplacizumab-yhdp in an amount ranging from about 100 mg/10 ml to about 200 mg/10 ml,
polysorbate-20 in an amount ranging from about 2 mg/10 ml to about 4 mg/10 ml,
sodium phosphate (monobasic, monohydrate) in an amount ranging from about 30.2 mg/10 ml to about 60.4 mg/10 ml,
sodium phosphate (dibasic) in an amount ranging from about 6.5 mg/10 ml to about 13 mg/10 ml;
wherein the pH of the pharmaceutical formulation is about 6.5
